ILX651
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone-refractory Prostate Cancer
Conditions
Hormone-refractory Prostate Cancer
Trial Timeline
— → Dec 1, 2005
NCT ID
NCT00082134About ILX651
ILX651 is a phase 2 stage product being developed by Sanofi for Hormone-refractory Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00082134. Target conditions include Hormone-refractory Prostate Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Hormone-refractory Prostate Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00082134 | Phase 2 | Completed |
| NCT00078455 | Phase 2 | Completed |
| NCT00068211 | Phase 2 | Completed |
Competing Products
8 competing products in Hormone-refractory Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzalutamide | Astellas Pharma | Phase 2 | 35 |
| YM598 | Astellas Pharma | Phase 2 | 27 |
| Zoledronic acid + Estramustine + Docetaxel | Novartis | Phase 2 | 35 |
| amg 162 | Amgen | Phase 3 | 40 |
| Denosumab | Amgen | Phase 3 | 40 |
| IV Bisphosphonate q 4 weeks | Amgen | Phase 2 | 35 |
| Dasatinib | Bristol Myers Squibb | Phase 2 | 35 |
| VIR-5500 | Vir Biotechnology | Phase 1 | 30 |